2023
Early Detection and Prognostic Assessment of Cutaneous Melanoma
Kashani-Sabet M, Leachman S, Stein J, Arbiser J, Berry E, Celebi J, Curiel-Lewandrowski C, Ferris L, Grant-Kels J, Grossman D, Kulkarni R, Marchetti M, Nelson K, Polsky D, Seiverling E, Swetter S, Tsao H, Verdieck-Devlaeminck A, Wei M, Bar A, Bartlett E, Bolognia J, Bowles T, B. K, Chu E, Hartman R, Hawryluk E, Jampel R, Karapetyan L, Kheterpal M, Lawson D, Leming P, Liebman T, Ming M, Sahni D, Savory S, Shaikh S, Sober A, Sondak V, Spaccarelli N, Usatine R, Venna S, Kirkwood J. Early Detection and Prognostic Assessment of Cutaneous Melanoma. JAMA Dermatology 2023, 159: 545-553. PMID: 36920356, PMCID: PMC11225588, DOI: 10.1001/jamadermatol.2023.0127.Peer-Reviewed Original ResearchConceptsRisk-stratified approachCutaneous melanomaGEP scorePrognostic assessmentGene expression profile testingMelanoma screeningEarly detectionLow-risk histologyNegative nodal statusDelphi consensus methodReflectance confocal microscopyNodal statusSentinel lymphAdvanced melanomaHistologic featuresScreening eventsScreening practicesConsensus statementConsensus recommendationsSkin lesionsDermoscopic examinationGEP testingConsensus conferenceMelanocytic skin lesionsClinical setting
2022
A methodological checklist for fMRI drug cue reactivity studies: development and expert consensus
Ekhtiari H, Zare-Bidoky M, Sangchooli A, Janes AC, Kaufman MJ, Oliver JA, Prisciandaro JJ, Wüstenberg T, Anton RF, Bach P, Baldacchino A, Beck A, Bjork JM, Brewer J, Childress AR, Claus ED, Courtney KE, Ebrahimi M, Filbey FM, Ghahremani DG, Azbari PG, Goldstein RZ, Goudriaan AE, Grodin EN, Hamilton JP, Hanlon CA, Hassani-Abharian P, Heinz A, Joseph JE, Kiefer F, Zonoozi AK, Kober H, Kuplicki R, Li Q, London ED, McClernon J, Noori HR, Owens MM, Paulus MP, Perini I, Potenza M, Potvin S, Ray L, Schacht JP, Seo D, Sinha R, Smolka MN, Spanagel R, Steele VR, Stein EA, Steins-Loeber S, Tapert SF, Verdejo-Garcia A, Vollstädt-Klein S, Wetherill RR, Wilson SJ, Witkiewitz K, Yuan K, Zhang X, Zilverstand A. A methodological checklist for fMRI drug cue reactivity studies: development and expert consensus. Nature Protocols 2022, 17: 567-595. PMID: 35121856, PMCID: PMC9063851, DOI: 10.1038/s41596-021-00649-4.Peer-Reviewed Original ResearchConceptsSubstance use disordersSystematic reviewReporting of itemsMagnetic resonance imaging studyDelphi consensus methodResonance imaging studyFunctional magnetic resonance imaging studyInitial checklistCue-reactivity studiesConsensus statementSUD treatmentConsensus paperUse disordersExpert consensusImaging studiesTask-based fMRICue reactivityIncomplete reportingMethodological checklistStructured recommendationsFMRI informationClinical translationChecklistFinal checklistReview
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply